Progress in the last year

MEDLINE
Stem Cell Research & Th erapy is now indexed by MEDLINE, the premier bibliographic database of the US National Library of Medicine. Each article record is indexed by using MeSH (Medical Subject Headings) terms, and thus the articles are highly accessible via PubMed. Readers can click straight through from PubMed to the Stem Cell Research & Th erapy website to read the open-access research articles without having to register or sign in. Th e fi nal published version of all articles is automatically deposited in PubMed Central; research articles are publicly available immediately upon publication, whereas subscription content, such as reviews and commentaries, becomes available a year after publication.
Thomson Reuters
Th omson Reuters (formerly the Institute for Scientifi c Information) (New York, NY, USA) has accepted Stem Cell Research & Th erapy for tracking from volume 1, issue 1, and the journal's fi rst (partial) impact factor is expected in the 2011 Journal Citation Report, which is to be published this summer. Th e early acceptance of Stem Cell Research & Th erapy is an indication of the journal's success in its fi rst few years of existence.
Growth of the journal
Th e journal received over 19,000 article accesses via the website in March 2012 and this fi gure has been growing each month. Th e two most accessed research articles published in 2011 have both received over 5,000 accesses so far; Jung Lim and colleagues [3] studied the eff ects of mesen chymal stem cells in a rat model of cerebral ischemia, and Alan Nixon's group [4] used fetal-derived embryonic-like stem cells to treat tendon injury in horses.
A review by editorial board member Christian Jorgensen and colleagues [5] on immunosuppression by mesenchymal stem cells remains our all-time most accessed article, having received nearly 16,000 accesses in the two years since its publication in March 2010.
Articles are regularly featured on the BMC Update, which is sent out fortnightly to more than 400,000 recipients. In addition, registrants on the journal website can sign up to receive article alerts on a daily, weekly, fortnightly, or monthly basis; new-issue alerts are sent out when each issue is complete. Readers can fi nd out how many times an article has been accessed or cited via the ' About this article' link from the right-hand side navigation bar, and via the 'My manuscripts' section of the website, authors can keep track of how many times their published articles have been accessed.
Our average time from submission to fi rst decision is 6 weeks, and the average time from submission to publication in 2011 was 20 weeks. We aim to continue to improve on this metric in the coming months.
Looking forward
Commissioned articles from opinion leaders in the fi eld are a key component of the journal. We aim to increase the relevance of this section to translational stem cell therapy research in the future. Upcoming commissioned content includes reviews from Nicholas Boulis and colleagues on stem cell therapy for the spinal cord and from Aastrom Biosciences (Ann Arbor, MI, USA) on its experience in developing a multicellular therapy expanded from a patient's own bone marrow. Th ese reviews will be published as part of a series on 'Clinical Our key objectives over the next few years are to increase the international reach and impact of the journal and to seek new and eff ective ways of engaging and communicating with our readers and contributors. Please do post a comment online or contact the editorial offi ce if you have suggestions for what developments you would like to see. Th ank you, as ever, to our editorial board, authors, reviewers, and readers for your support.
